Yüklüyor......
Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator
To date, data on effectiveness and safety of Adalimumab (ADA) biosimilars in inflammatory bowel diseases (IBDs) are lacking. Therefore, we aimed to verify the ability of ABP501 and SB5 to maintain the clinical and biochemical response induced by the ADA originator, after switching to them. We prospe...
Kaydedildi:
| Yayımlandı: | Sci Rep |
|---|---|
| Asıl Yazarlar: | , , , , , , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Nature Publishing Group UK
2021
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8121777/ https://ncbi.nlm.nih.gov/pubmed/33990652 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-021-89790-4 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|